Literature DB >> 27074922

Vonoprazan: MarKed Competition for PPIs?

David R Scott1,2, Elizabeth A Marcus3,4, George Sachs5,6,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27074922      PMCID： PMC4920708          DOI： 10.1007/s10620-016-4164-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  12 in total

1.  Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients.

Authors:  C Cederberg; T Lind; K Röhss; L Olbe
Journal:  Digestion       Date:  1992       Impact factor: 3.216

Review 2.  Omeprazole: the first proton pump inhibitor.

Authors:  P Lindberg; A Brändström; B Wallmark; H Mattsson; L Rikner; K J Hoffmann
Journal:  Med Res Rev       Date:  1990 Jan-Mar       Impact factor: 12.944

Review 3.  Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.

Authors:  Kjell Andersson; Enar Carlsson
Journal:  Pharmacol Ther       Date:  2005-07-05       Impact factor: 12.310

4.  Inhibition of gastric H+,K+-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1,2a)imidazole.

Authors:  B Wallmark; C Briving; J Fryklund; K Munson; R Jackson; J Mendlein; E Rabon; G Sachs
Journal:  J Biol Chem       Date:  1987-02-15       Impact factor: 5.157

5.  A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands.

Authors:  Jun Matsukawa; Yasunobu Hori; Haruyuki Nishida; Masahiro Kajino; Nobuhiro Inatomi
Journal:  Biochem Pharmacol       Date:  2011-03-01       Impact factor: 5.858

6.  Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa.

Authors:  Jun Matsukawa; Akifumi Kogame; Yoshihiko Tagawa; Nobuhiro Inatomi
Journal:  Dig Dis Sci       Date:  2016-03-09       Impact factor: 3.199

Review 7.  Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori.

Authors:  T Furuta; N Shirai; K Ohashi; T Ishizaki
Journal:  Methods Find Exp Clin Pharmacol       Date:  2003-03

8.  Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion.

Authors:  K Gedda; D Scott; M Besancon; P Lorentzon; G Sachs
Journal:  Gastroenterology       Date:  1995-10       Impact factor: 22.682

9.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.

Authors:  Yuuichi Sakurai; Akira Nishimura; Gale Kennedy; Mark Hibberd; Richard Jenkins; Hiroyuki Okamoto; Tomoki Yoneyama; Helen Jenkins; Kiyoshi Ashida; Shin Irie; Jörg Täubel
Journal:  Clin Transl Gastroenterol       Date:  2015-06-25       Impact factor: 4.488

10.  Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.

Authors:  K Ashida; Y Sakurai; A Nishimura; K Kudou; N Hiramatsu; E Umegaki; K Iwakiri; T Chiba
Journal:  Aliment Pharmacol Ther       Date:  2015-07-22       Impact factor: 8.171
View more
  1 in total

1.  Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.

Authors:  Ki Young Huh; Hyewon Chung; Yu Kyong Kim; SeungHwan Lee; Siddharth Bhatia; Yohei Takanami; Ryou Nakaya; Kyung-Sang Yu
Journal:  Br J Clin Pharmacol       Date:  2021-06-26       Impact factor: 3.716
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.